| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5919479 | TARO | Noninvasive dermal anesthetics |
Jul, 2015
(8 years ago) | |
| US6528086 | TARO | Methods and apparatus for drug delivery involving phase changing formulations |
Sep, 2019
(4 years ago) | |
| US10603293 | TARO | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(6 years from now) | |
| US10350180 | TARO | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(6 years from now) | |
| US10751305 | TARO | Solid-forming topical formulations for pain control |
Jan, 2031
(6 years from now) | |
Pliaglis is owned by Taro.
Pliaglis contains Lidocaine; Tetracaine.
Pliaglis has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Pliaglis are:
- US5919479
- US6528086
Pliaglis was authorised for market use on 29 June, 2006.
Pliaglis is available in cream;topical dosage forms.
The generics of Pliaglis are possible to be released after 14 January, 2031.
Drugs and Companies using LIDOCAINE; TETRACAINE ingredient
Market Authorisation Date: 29 June, 2006
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
PLIAGLIS family patents
